Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506	Hold	3	–	–	﹤0.01%	751
2026 Q1	$395	Hold	3	–	–	﹤0.01%	772
2025 Q4	$425	Buy	+3	New	+$435	﹤0.01%	742

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Trust Company's NBIX Position: Q2 2026 in Review

Trust Company held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 3 shares worth $506. The position accounts for ﹤0.01% of the portfolio, ranked #751.

Trust Company first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Trust Company held 3 shares of Neurocrine Biosciences worth $506 as of Q2 2026.
Trust Company left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #751 holding.
Trust Company first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.